TGTX · TG Therapeutics, Inc.
$56.04
-1.58% last session
End-of-day data · updated 2026-07-28
Market cap
$9B
Enterprise value
$8B
Trailing P/E
19.5
Forward P/E
17.0
Dividend yield
—
Beta
1.60
Avg volume
2M
Employees
0K
2D change
—
5D change
0.45%
10D change
1.60%
30D change
-0.14%
60D change
46.94%
MTD change
4.17%
YTD change
87.02%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TGTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-27
Latest call per bank · past 12 months
Bank of America
Underperform$20.00
-64.3% vs priceJP Morgan
Overweight$46.00
-17.9% vs priceGoldman Sachs
Neutral$39.00
-30.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-27 | B. Riley Securities | Maintains | Buy | $55.00 → $86.00 |
| 2026-07-13 | HC Wainwright & Co. | Maintains | Buy | $70.00 → $77.00 |
| 2026-07-07 | Bank of America | Maintains | Underperform | $17.00 → $20.00 |
| 2026-07-06 | HC Wainwright & Co. | Reiterates | Buy | $70.00 |
| 2026-05-27 | HC Wainwright & Co. | Reiterates | Buy | $70.00 |
| 2026-05-06 | HC Wainwright & Co. | Maintains | Buy | $60.00 → $70.00 |
| 2026-02-02 | JP Morgan | Maintains | Overweight | $49.00 → $46.00 |
| 2026-01-15 | Goldman Sachs | Maintains | Neutral | $37.00 → $39.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.7% above the 50-day MA ($49.11).
- Price vs 200-day MA: Trading 50.7% above the 200-day MA ($36.40).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.53) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($26.39) and high ($59.06).
TGTX Price Chart
Loading chart for TGTX…
Fundamentals
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.